<DOC>
	<DOCNO>NCT02560766</DOCNO>
	<brief_summary>The primary objective trial evaluate efficacy HORIZANT 300 mg 600 mg , compare placebo , 12 week treatment , treatment Restless Legs Syndrome ( RLS ) adolescent ( 13 17 year age ) diagnose moderate-to-severe primary RLS .</brief_summary>
	<brief_title>An Efficacy Safety Evaluation HORIZANT Adolescents With Moderate-to-Severe Primary RLS</brief_title>
	<detailed_description />
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>1 . Male female adolescent patient , age 13 17 year , diagnose RLS base IRLSSG consensus criterion ( Allen RP 2014 ) ( Appendix 2 ) . 2 . Total RLS severity score 15 great IRLS rating scale Visit 1 ( screen ) Visit 2 ( baseline ) ( Appendix 8 ) . 3 . RLS symptoms least 4 7 consecutive evenings/nights screen period . 4 . Body weight great 33.4 kg healthy weight use agebased body mass index ( BMI ) range 5th85th percentile screen baseline . Appendix 3 contains BMIforage chart consult . 5 . Estimated creatinine clearance least 60 mL/min ( use CockcroftGault equation ) screening . 6 . Signed patient parent Institutional Review Board ( IRB ) approve informed consent/assent form ( applicable ) studyrelated procedure perform . 1 . History primary sleep disorder RLS may significantly affect symptom RLS . 2 . Serum ferritin level &lt; 20 ng/mL screening . 3 . History allergy , hypersensitivity , intolerance HORIZANT gabapentin product ( eg , Neurontin® , Gralise® ) . 4 . Suffering movement disorder could mimic confound accurate diagnosis RLS ( eg , Tourette 's syndrome , tic disorder , periodic limb movement disorder [ PLMD ] , sleep disorder ) . 5 . Currently meet Diagnostic Statistical Manual Mental Disorders Fifth Edition ( DSM5 ) criterion substance use disorder , history thereof , within 12 month dose . 6 . Current past history significant psychiatric disorder include , limited , depression ( treatment antidepressant ) , bipolar disorder , schizophrenia . 7 . Diagnosis attentiondeficit hyperactivity disorder ( ADHD ) allow , provide patient receive medication ( ) know affect assessment RLS . 8 . History suicidal behavior suicidal ideation indicate CSSRS , administer screening ( questionnaire provide Appendix 4 ) , per investigator 's judgment . 9 . History seizure disorder increase risk development seizure disorder include , limited , complicate febrile seizure history significant head injury . 10 . Medical condition disorder would interfere action , absorption , distribution , metabolism , excretion gabapentin enacarbil , , investigator 's judgment consider clinically significant may pose safety concern , , could interfere accurate assessment safety efficacy , could potentially affect patient 's safety study outcome . 11 . Clinically significant abnormal laboratory result physical examination find resolved time baseline assessment .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Restless Leg Syndrome</keyword>
	<keyword>RLS</keyword>
</DOC>